CytRx Corp

CYTR:OTCQB
RT Quote | Exchange | USD
Last | 01/25/21 EST
2.20UNCH (UNCH)
52 week range
0.35 - 2.75

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.20
  • 52 Week High2.75
  • 52 Week High Date01/14/21
  • 52 Week Low0.35
  • 52 Week Low Date03/18/20
  • Market Cap80.26M
  • Shares Out36.48M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.05
  • 1 Year % Change229.59

RATIOS/PROFITABILITY

  • EPS (TTM)-0.24
  • P/E (TTM)-9.07
  • Fwd P/E (NTM)-20.00
  • EBITDA (MRQ)-8.42M
  • ROE (MRQ)-60.94%
  • Revenue (MRQ)0.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,697.00%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest CytRx Corp News

There is no recent news for this security.

Latest CYTR News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical...
Steven Kriegsman
Chairman
John Caloz
Chief Financial Officer
Address
11726 San Vicente Blvd Ste 650
Los Angeles, CA
90049-5079
United States